Anesthesiologists and the pharmaceutical industry: awareness is paramount

  • François Hélie
  • Jean-François Hardy
  • Keyvan Karkouti
Correspondence
  • 241 Downloads

References

  1. 1a.
    Karkouti K, Beattie WS, Crowther MA, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anesth 2007; 54: 573–82.PubMedGoogle Scholar
  2. 2.
    ChChina TS, Lapierre H, Jackson ZS, et al. Effect of recombinant factor VIIa on rabbit vascular graft patency. Can J Anesth 2004; 51: A1 (abstract).Google Scholar
  3. 3.
    Godier A, Mazoyer E, Cymbalista F, Cupa M, Samama CM. Recombinant activated factor VII efficacy and safety in a model of bleeding and thrombosis in hypothermic rabbits: a blind study. J Thromb Haemost 2007; 5: 244–9.PubMedCrossRefGoogle Scholar
  4. 4.
    Charbonneau S, Girard F, Boudreault D, Ruel M, Blais N, Hardy JF. Recombinant human activated factor VII is thrombogenic in a rabbit model of cyclic flow reduction and does not reduce intra-abdominal bleeding. Thromb Haemost 2007; 97: 296–303.PubMedGoogle Scholar
  5. 5.
    Blumenthal D. Doctors and drug companies. N Engl J Med 2004; 351: 1885–90.PubMedCrossRefGoogle Scholar
  6. 6.
    Mayer SA, Brun NC, Begtrup K, et al. Recombinant activated factor VII for acute intracerebral hemorrhage. N Engl J Med 2005; 352: 777–85.PubMedCrossRefGoogle Scholar
  7. 7.
    Lewis S, Baird P, Evans RG, et al. Dancing with the porcupine: rules for governing the university-industry relationship. CMAJ 2001; 165: 783–5.PubMedGoogle Scholar

References

  1. 1b.
    Karkouti K, Beattie WS, Crowther MA, et al. The role of recombinant factor VIIa in on-pump cardiac surgery: proceedings of the Canadian Consensus Conference. Can J Anesth 2007; 54: 573–82.PubMedGoogle Scholar
  2. 2.
    Bekelman JE, Li Y, Gross CP. Scope and impact of financial conflicts of interest in biomedical research: a systematic review. JAMA 2003; 289: 454–65.PubMedCrossRefGoogle Scholar
  3. 3.
    Karkouti K, Wijeysundera D, Beattie WS, Yau T. Variability and predictability of blood product use in cardiac surgery: a multicentre study. Transfusion 2007; doi:10.1111/j.1537-2995.2007.01432.x.Google Scholar
  4. 4.
    Fattorutto M, Tourreau-Pham S, Mazoyer E, et al. Recombinant activated factor VII decreases bleeding without increasing arterial thrombosis in rabbits. Can J Anesth 2004; 51: 672–9.PubMedGoogle Scholar
  5. 5.
    Karkouti K, Yau TM, Riazi S, et al. Determinants of complications with recombinant factor VIIa for refractory blood loss in cardiac surgery. Can J Anesth 2006; 53: 802–9.PubMedCrossRefGoogle Scholar
  6. 6.
    Karkouti K, Wijeysundera DN, Yau TM, et al. Platelet transfusions are not associated with increased morbidity or mortality in cardiac surgery. Can J Anesth 2006; 53: 279–87.PubMedGoogle Scholar
  7. 7.
    Karkouti K, Wijeysundera DN, Yau TM, et al. The independent association of massive blood loss with mortality in cardiac surgery. Transfusion 2004; 44: 1453–62.PubMedCrossRefGoogle Scholar

Copyright information

© Canadian Anesthesiologists 2007

Authors and Affiliations

  • François Hélie
    • 1
  • Jean-François Hardy
    • 1
  • Keyvan Karkouti
    • 2
  1. 1.CHUM Hôpital Notre-DameMontrealCanada
  2. 2.Toronto General HospitalUniversity of TorontoTorontoCanada

Personalised recommendations